PHSI-BRG
PHSI-BRG
Home
Staff
Sarah Al Ashmori
Andy Bryant
Thomas Chadwick
Svetlana Cherlin
Mike Cole
Holly Fisher
Tony Fouweather
Shaun Hiu
Dorcas Kareithi
Ann Breeze Konkoth
Nan Lin
Jingky Lozano-Kuehne
Helen Mossop
Ellen Moss
Aritra Mukherjee
Jérémie Nsengimana
Vicky Ryan
Marzieh Shahmandi
Moha Shojaei
Dawn Teare
James Wason
Faye Williamson
Nina Wilson
Sylvia Zhang
PhD students
Ruqayya Azher
Nicole Cizauskas
Laura Etfer
Niamh Fitzgerald
Raiann Hamshaw
Pela Okorie
Samuel Sarkodie
Lou Whitehead
Methodology research
Overview
Adaptive designs
Master protocols
Transforming IMID trials
Projects
Publications
News
Courses
Adaptive Designs and Multiple Testing Procedures
Leveraging External Information
Precision Medicine Clinical Trials
Contact
Light
Dark
Automatic
Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia
Fordham SE
,
Cole M
,
Irving JA
,
Allan JM
September 2014
DOI
Type
Journal article
Publication
Leukemia
2015; 29(2):491-494
Cole
Related
Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves’ disease
Adjuvant Rituximab—Exploratory Trial in Young People With Graves Disease
Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition
Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): Study protocol for a single-arm, single-stage, phase II trial
Drooling Reduction Intervention randomised trial (DRI): Comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability
Cite
×